Narendra Investment (Delhi) Limited enters into slump sale agreement with Urvi Speciality Chemicals
Posted On:
2021-03-01 10:57:47
(Time Zone: Arizona, USA)
The Board of Directors of Narendra Investment (Delhi) Limited ('The Company') at its meeting held today commenced at 11.30 am and concluded at 7.15 pm has approved and taken on record the in-principal approval letter dated February 26, 2021 received from Registrar of Companies, Central Registration Centre, reserving the change of name from 'NARENDRA INVESTMENTS (DELHI) LIMITED' to 'EIKO LIFE SCIENCES LIMITED'.
The board approved raising of funds by issue of securities on preferential basis, subject to necessary shareholders / regulatory approvals, as applicable. The Board of Directors, at its meeting held today, has taken note of the investors who have individually expressed their agreement / willingness to subscribe upto 24,29,967 Equity Shares of Rs. 10/- each, being issued at a price of Rs. 30/- per share including Rs. 20/-per share towards the share premium for an aggregate amount upto Rs. 7,28,99,010/- which shall be undertaken on a preferential allotment basis.